Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
Abstract Background Galcanezumab is a novel monoclonal antibody that target to calcitonin gene-related peptide (CGRP). It has been tested for the preventive treatment of migraine and episodic cluster headache by multiple randomized clinical trials (RCTs) and have been found to reduce headache freque...
| Published in: | The Journal of Headache and Pain |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-02-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10194-020-1085-x |